Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrum ABFRA:6Y1 +2.90%52 10-Year ROIIC % is -26.32 as of Apr. 2026. GuruFocus rates FRA:6Y1 with a GF Score™ of 52/100 and a GF Value™ of €1.54 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Integrum AB ranks worse than 74.96% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Integrum AB's 10-Year ROIIC % for the quarter that ended in Apr. 2026 was -26.32%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Integrum AB's 10-Year ROIIC % or its related term are showing as below:
FRA:6Y1's 10-Year ROIIC % is ranked worse than 74.96% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 2.29
vs FRA:6Y1: -26.32
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Integrum AB 10-Year ROIIC % Related Terms
Integrum AB 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Integrum AB's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Y1 vs ABT, SYK, MDT: 10-Year ROIIC % Comparison
For the Medical Devices subindustry, Integrum AB's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Integrum AB's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Integrum AB (FRA:6Y1) has a 10-Year ROIIC % of -26.32 as of Apr. 2026. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Integrum AB and its competitors. According to the industry distribution chart, Integrum AB ranks #518 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 75%.
Is Integrum AB's 10-Year ROIIC % too high?
Integrum AB's current 10-Year ROIIC % is -26.32. Based on the distribution chart, Integrum AB ranks #518 out of 691 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Integrum AB has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's 10-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #518 out of 691 companies for 10-Year ROIIC %. This places Integrum AB in the lower half of its industry. The industry median 10-Year ROIIC % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.29, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Integrum AB and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current 10-Year ROIIC % is -26.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (FRA:6Y1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.71 — trading 54% below its estimated fair value. The current 10-Year ROIIC % is -26.32. Integrum AB's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Integrum AB (FRA:6Y1), the current 10-Year ROIIC % is -26.32 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (FRA:6Y1) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of €0.71 is trading 54% below its estimated GF Value™ of €1.54.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for FRA:6Y1:
10-Year ROIIC %: -26.32
GF Value™: €1.54 vs. price of €0.71 (54% below fair value)
No single metric tells the full story. See the FRA:6Y1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
52GF Score
Get the complete analysis for FRA:6Y1
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Y1 has been successfully added to your 
